Salute e Benessere
Navamedic ASA: Broad launch for Eroxon® in Sweden today
"Eroxon® is a fast, safe and easily available product developed to help men improve not only their sexual health but also their quality of life. We hope for a similar response in Sweden as in the UK and Norway . Over time, we see greater growth potential in Sweden because Eroxon® will be the only non-prescription treatment for erectile dysfunction in the market," says Jack Spira , Medical Director at Navamedic.
Four out of ten men in Sweden have experienced erectile dysfunction at some point, according to a new survey conducted on behalf of Navamedic. Medication is the most common measure, but the vast majority do not seek any help at all .
Eroxon® offers a range of features which distinguishes it from other treatments of erectile dysfunction. First and foremost, it is an effective and fast-acting gel which typically helps men get an erection within ten minutes. It has a very good safety profile due to local effect with no systemic absorption. Eroxon® is approved as a treatment for erectile dysfunction in the EU and the US.
Survey conducted in Sweden by Novus 28 March – 11 April 2024 .
Kathrine Gamborg Andreassen , CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/navamedic-asa-broad-launch-for-eroxon-in-sweden-today-302136644.html